Alzheimer’s disease (AD) is the most common neurodegenerative cause of dementia, characterized by progressive cognitive decline that impairs memory, language, executive function, and ultimately activities of daily living. The disorder is driven by neuropathological hallmarks—extracellular amyloid-beta (Aβ) plaques, intracellular hyperphosphorylated tau neurofibrillary tangles, and downstream synaptic and neuronal loss. Although symptoms appear gradually, the underlying biological cascade begins years to decades earlier, making early identification and disease-modifying treatment critical.
From a mechanistic perspective, AD is often explained through the interaction of Aβ pathology and tau pathology. Aβ accumulates due to altered production and clearance, including dysregulation of amyloid precursor protein processing by β- and γ-secretases and impaired elimination via glymphatic and microglial pathways. As soluble Aβ species accumulate, they may promote neuroinflammation, oxidative stress, and synaptic dysfunction. Tau, a microtubule-associated protein, becomes abnormally phosphorylated and aggregates into paired helical filaments that spread in a pattern consistent with neuronal network connectivity. This progression aligns with clinical trajectories: early episodic memory impairment typically reflects medial temporal lobe involvement, while later widespread cortical involvement correlates with language deficits, visuospatial dysfunction, and impaired planning.
Clinically, AD is staged along a continuum from preclinical disease (no overt cognitive impairment but evidence of AD biomarkers) to mild cognitive impairment (MCI) due to AD and to dementia due to AD. In MCI, patients show measurable cognitive decline beyond age- and education-expected norms but preserve largely independent function. In dementia, cognitive deficits are severe enough to interfere with independence, with deficits spanning multiple cognitive domains. Behavioral and psychological symptoms of dementia—such as agitation, anxiety, depression, sleep disturbance, and hallucinations—are common and reflect limbic and cortical network dysfunction.
Diagnosis requires integrating clinical assessment with biomarker and exclusion of alternative etiologies. A comprehensive history and cognitive testing (often using standardized neuropsychological batteries) establish the pattern and severity of impairment. Laboratory studies and neuroimaging help rule out reversible causes (e.g., vitamin deficiencies, thyroid disorders, normal-pressure hydrocephalus, medication effects). Structural MRI can demonstrate atrophy patterns, including medial temporal lobe and hippocampal volume loss. Functional imaging may show hypometabolism, and amyloid and tau biomarkers can be measured through cerebrospinal fluid analysis or positron emission tomography. Current diagnostic approaches prioritize biomarker-confirmed AD when possible, especially in atypical presentations or early disease stages.
Treatment for AD is multifaceted, combining symptomatic therapies, disease-modifying options for eligible patients, and comprehensive supportive care. Cholinesterase inhibitors (such as donepezil, rivastigmine, and galantamine) can modestly improve cognitive symptoms and delay worsening of function in mild-to-moderate AD. Memantine, an NMDA receptor antagonist, may help in moderate-to-severe stages by reducing excitotoxicity and improving neurocognitive function in some patients. These medications do not halt the core pathology but can improve quality of life and caregiver burden.
Disease-modifying treatments have emerged that target amyloid pathology by reducing amyloid burden or altering downstream processes. Eligibility generally depends on disease stage, biomarker evidence, and risk-benefit considerations. A key safety issue is amyloid-related imaging abnormalities (ARIA), including vasogenic edema and microhemorrhages detected on MRI. Ongoing monitoring and careful patient selection are essential. Beyond anti-amyloid therapies, research is exploring anti-tau strategies, anti-inflammatory modulation, neuroprotective approaches, and combination regimens.
Nonpharmacologic management is equally important. Evidence supports structured routines, cognitive stimulation, exercise programs tailored to physical capacity, sleep optimization, and management of sensory impairments (e.g., hearing loss) to reduce cognitive load and behavioral symptoms. Care planning should address safety (driving, medication management, fall prevention), nutrition, and advance directives. Psychosocial interventions can mitigate depression and anxiety in patients and provide coping resources for caregivers.
Given the long preclinical phase, prevention and risk reduction strategies are actively studied. While there is no guaranteed prevention, modifiable vascular and lifestyle risks—such as hypertension, diabetes, obesity, smoking, sedentary behavior, and hearing loss—are associated with higher dementia risk. Managing cardiovascular risk may help preserve brain resilience by reducing microvascular injury and inflammation.
Prognostically, AD is progressive, though the pace varies. Neurodegeneration leads to increasing dependence over time, and mortality often relates to complications such as infections, aspiration, and frailty. Therefore, early diagnosis, timely initiation of appropriate therapies, and multidisciplinary care can meaningfully influence outcomes.
Source: @cheer_nunu06 (original post on X)
goofy goober: @CoryThomps59321 @Shafiuharmless1 She needed up becoming cheif of general surgery, multiple medals, and now finding a cure for Alzheimer’s. They have to go around and find what best fits them. For her neuro wasn’t her thing general was her thing. #breaking
— @cheer_nunu06 May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
